Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.36 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | LSS | P48449 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6090430 | 0.87 | PARP1 (0.42) | PARP1ESR1HRH3CACNA1BMAOB | |
| SCHEMBL6090501 | 0.82 | BRD4 (0.36) | KDM4EALDH1A1GAA | |
| SCHEMBL6090493 | 0.82 | BRD4 (0.36) | KDM4EALDH1A1GAA | |
| SCHEMBL6089038 | 0.79 | ESR1 (0.36) | PARP1ESR1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL6089041 | 0.79 | ESR1 (0.36) | PARP1ESR1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL6091022 | 0.79 | PARP1 (0.40) | PARP1ESR1HRH3CACNA1BMAOB | |
| SCHEMBL6091436 | 0.79 | PARP1 (0.40) | PARP1ESR1HRH3CACNA1BMAOB | |
| SCHEMBL6090917 | 0.78 | MEN1 (0.40) | KDM4EALDH1A1SMN1; SMN2GAALMNA | |
| SCHEMBL6090911 | 0.78 | MEN1 (0.40) | KDM4EALDH1A1SMN1; SMN2GAALMNA | |
| SCHEMBL6091800 | 0.77 | ALDH1A1 (0.44) | KDM4EALDH1A1SMN1; SMN2GAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060004028-A1 | Novel PARP inhibitor | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004028-A1 | Novel PARP inhibitor | PARP1, PARP2, PARP11 | PARP1 1/4885ESR1 2745/4885HRH3 2623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.